Efficacy and safety of Avalglucosidase Alfa in participants with late-onset Pompe Disease after 145 weeks' treatment during the COMET trial

Schoser B., Kishnani P., Kushlaf H., Ladha S., Mozaffar T., Straub V., ...Daha Fazla

NEUROMUSCULAR DISORDERS, cilt.32, 2022 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Özet
  • Cilt numarası: 32
  • Basım Tarihi: 2022
  • Dergi Adı: NEUROMUSCULAR DISORDERS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Hacettepe Üniversitesi Adresli: Evet